ACM Research, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ACM Research, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $74.64M | Mar 14, 2019 |
| FY2018 | Dec 31, 2017 | $36.51M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $27.37M | Mar 23, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $901.31M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $782.12M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $557.72M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $388.83M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $259.75M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $156.62M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $107.52M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $74.64M | Mar 1, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $400.07M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $391.55M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $276.22M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $183.62M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $114.86M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $69.60M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $50.65M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $34.45M | Mar 1, 2021 |
| FY2018 | Dec 31, 2017 | $17.23M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $13.33M | Mar 23, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.08M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $103.63M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $77.35M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $39.26M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $37.76M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $18.78M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $18.89M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $6.57M | Mar 1, 2021 |
| FY2018 | Dec 31, 2017 | ($318.0K) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.03M | Mar 23, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.43M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $151.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $95.84M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $59.04M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $38.70M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $21.49M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $17.79M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $6.47M | Mar 1, 2021 |
| FY2018 | Dec 31, 2017 | $700.0K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $3.49M | Mar 23, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $144.99M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $105.47M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $92.71M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $62.23M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $34.21M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $19.12M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $12.90M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $10.38M | Mar 1, 2021 |
| FY2018 | Dec 31, 2017 | $5.14M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $3.26M | Mar 23, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.33M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $152.45M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($75.32M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($62.19M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($40.09M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($13.55M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $9.40M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $6.91M | Mar 1, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.28M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $82.46M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $61.88M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $91.09M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $9.15M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $5.21M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $971.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $1.83M | Mar 1, 2021 |
| FY2018 | Dec 31, 2017 | $651.0K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $795.0K | Mar 23, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.87B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.86B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.49B | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $1.24B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.05B | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $341.26M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $217.70M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $103.05M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $67.89M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $44.47M | Mar 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $941.68M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $759.82M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $564.75M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $423.33M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $240.51M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $133.09M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $60.22M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $50.72M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $28.03M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $23.95M | Mar 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.46B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $904.63M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $767.39M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $674.86M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $676.20M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $141.15M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $97.32M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $52.32M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $39.86M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($2.43M) | Mar 23, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $350.43M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $260.00M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $156.83M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $94.43M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $63.73M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $34.29M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $15.51M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($3.39M) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($9.96M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($9.64M) | Mar 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $757.37M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $407.45M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $182.09M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $247.95M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $562.55M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $71.77M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $58.26M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $27.12M | Mar 1, 2021 |
| FY2018 | Dec 31, 2017 | $17.68M | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | $10.12M | Mar 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $214.01M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $150.00M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $60.74M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $21.01M | Feb 28, 2024 |
| FY2021 | Dec 31, 2021 | $25.37M | Mar 1, 2022 |
| FY2020 | Dec 31, 2020 | $19.57M | Mar 1, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 1, 2021 |
| FY2018 | Dec 31, 2017 | 0 | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 23, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 1, 2021 |
| FY2018 | Dec 31, 2017 | 0 | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 23, 2018 |